|1.||Reijerkerk, Arie: 2 articles (01/2012 - 09/2010)|
|2.||Ronken, Eric: 2 articles (01/2012 - 09/2010)|
|3.||Lakeman, Kim: 2 articles (01/2012 - 09/2010)|
|4.||Osinde, Maribel: 2 articles (08/2007 - 04/2007)|
|5.||Dev, Kumlesh K: 2 articles (08/2007 - 04/2007)|
|6.||Mullershausen, Florian: 2 articles (08/2007 - 04/2007)|
|7.||Hartung, Hans-Peter: 1 article (09/2015)|
|8.||Küry, Patrick: 1 article (09/2015)|
|9.||Heinen, André: 1 article (09/2015)|
|10.||Tzekova, Nevena: 1 article (09/2015)|
08/26/2011 - "FTY720P, the bioactive form of a drug currently used to treat multiple sclerosis, inhibits ATX in an uncompetitive manner and slows the hydrolysis reaction, suggesting that ATX inhibition plays a significant role in lymphocyte immobilization in FTY720P-based therapeutics."
08/01/2007 - "The phosphorylated version of fingolimod/FTY720 (FTY720P) is active on a broad spectrum of S1P receptors and the parent compound is currently in phase III clinical trials for the treatment of multiple sclerosis. "
04/01/2007 - "Fingolimod (FTY720) is in phase III clinical trials for the treatment of multiple sclerosis and its phosphorylated version (FTY720P) activates S1P receptors. "
08/01/2007 - "We suggest that this distinct pharmacological profile of FTY720P, compared with S1P, could play a role in the therapeutic effects of FTY720 in multiple sclerosis."
09/01/2010 - "Phosphorylated FTY720 (FTY720P) is a sphingosine 1-phosphate (S1P) analogue that is currently in trial for treatment of multiple sclerosis (MS), which targets all S1P receptors but S1P(2). "
|2.||Wounds and Injuries (Trauma)
|2.||sphingosine 1-phosphate (sphingosine-1-phosphate)